person Sign In / Create Account

A New Drug for Relapsed/Refractory Myeloma Patients: Melflufen

Relapsed/Refractory Myeloma Chapter

Apr 02, 2021 / 07:00PM - 08:00PM EDT

Watch Recording

Event Description

Name: A New Drug for Relapsed/Refractory Myeloma Patients: Melflufen
Start: 2021-04-02T19:00:00-04:00
End: 2021-04-02T20:00:00-04:00

A new treatment for multiple myeloma called melflufen (PEPAXTO®) was recently FDA-approved for relapsed or refractory multiple myeloma patients who have received at least four prior lines of therapy. Join us to hear Dr. Agne Paner of Rush University explain what the new therapy is, who qualifies for it, when it should be considered and how it works. Come with questions for the Q&A!

Schedule & Agenda

Introductions

07:00PM

Jenny Ahlstrom

Jenny introduces the new Myeloma Community Chapter, the event agenda, and our featured speaker, Dr. Agne Paner.

07:00PM

Jenny Ahlstrom

Introductions

Jenny introduces the new Myeloma Community Chapter, the event agenda, and our featured speaker, Dr. Agne Paner.

Presentation

07:05PM

Dr. Agne Paner

Dr. Paner explains what the melflufen is, who qualifies for it, and how it works. Come with questions!

07:05PM

Dr. Agne Paner

Presentation

Dr. Paner explains what the melflufen is, who qualifies for it, and how it works. Come with questions!

Questions and Answers

07:40PM

Audience

Ask your questions about this new treatment to Dr. Paner!

07:40PM

Audience

Questions and Answers

Ask your questions about this new treatment to Dr. Paner!

Speakers & Moderators

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Dr. Agne Paner

Dr. Paner is an Associate Professor of Medicine in the Multiple Myeloma and Amyloidosis Program at Rush Medical College. Her research interests include clinical trials with innovative approaches to the treatment of patients with multiple myeloma and amyloidosis. She had hands-on experience in the HORIZON trial. She has been treating multiple myeloma for over 10 years and takes care of about 200 patients with multiple myeloma a year.

Read Bio